Abstract:Background: Recent studies have reported that an elevated intracellular glutathione (GSH) level is associated with resistance of non-small cell lung cancer (NSCLC) cell lines to cisplatin (CDDP). It is well-known that GSH is widely used in the clinic as a hepatoprotective agent. However, whether exogenous GSH can affect the sensitivity of NSCLC cells to CDDP remains unclear. The aim of this study is to evaluate the role of exogenous GSH in the resistance of A549 cells to CDDP. Methods: The effect of GSH and CDDP on the proliferation of A549 cells was analyzed by MTT assay. Subsequent experiments were conducted in A549 cells divided into four groups: control group (untreated cells), GSH group (treated with 120 mu g/ml GSH for 48 N. CDDP group (treated with 10 mu G/ml CDDP for 48 h) and CDDP+GSH group (treated with 10 mu g/ml CDDP+120 mu g/ml GSH for 48 M. Apoptosis was detected by flow cytometry. Light microscopy, fluorescence microscopy and electron microscopy were performed to study morphologic and ultrastructural differences among the four groups of cells. Intracellular GSH level and gamma-GCS expression were determined by immunohistochemistry (IHC). Cellular platinum uptake was assessed by inductively coupled plasma mass spectrometry (ICP-MS). Quantitative RT-PCR analysis was performed to measure the expression of caspase3, caspase9, bax, bc1-2 and MDR-1. Western blot analysis was conducted to examine the protein levels of GST-n, MRP-1 and P-gp. Results: Growth inhibition and apoptosis were reduced in A549 cells in the CDDP+GSH group compared to those in the CDDP group 48 h post-treatment. Alterations in cellular morphology and ultrastructure, as well as typical characteristics of apoptosis, were observed. Intracellular GSH and gamma-GCS levels were elevated by exogenous administration of GSH; in contrast, cellular platinum concentration fell rapidly. Relative to the CDDP group, the CDDP+GSH group exhibited 47.92%, 47.82% and 63.75% downregulation in caspase3, caspase9 and bax mRNA expression, respectively, and a 2.17-fold increase in bc1-2 mRNA level. In addition, there were 1.58-fold and 2.67-fold increases in the level of GST-n and MRP-1, respectively; however, the changes in MDR-1 and P-gp levels were not statistically significant. Conclusions: Our data demonstrated that exogenous GSH used as hepatinica in the clinic could induce resistance of A549 cells to CDDP by inhibiting apoptosis, elevating cellular GSH levels, inactivating the mitochondria-mediated signaling pathway, and increasingthe expression of GST-n, y-GCS and MRP1 to increase CDDP efflux.

Inhibition of Glucose-6-Phosphate Dehydrogenase Reverses Cisplatin Resistance in Lung Cancer Cells Via the Redox System

Inhibition of 6-Phosphogluconate Dehydrogenase Reverses Cisplatin Resistance in Ovarian and Lung Cancer.

Modulation of G6PD Affects Bladder Cancer Via ROS Accumulation and the AKT Pathway in Vitro.

Targeting cisplatin-resistant human tumor cells with metabolic inhibitors

1-Hydroxy-8-methoxy-anthraquinon Reverses Cisplatin Resistance by Inhibiting 6PGD in Cancer Cells

The Pentose Phosphate Pathway and Its Involvement in Cisplatin Resistance

ABT737 Reverses Cisplatin Resistance by Targeting Glucose Metabolism of Human Ovarian Cancer Cells

Disrupting G6PD-mediated Redox Homeostasis Enhances Chemosensitivity in Colorectal Cancer

The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer

O-GlcNAcylation of G6PD Promotes the Pentose Phosphate Pathway and Tumor Growth

Integration of metabolomics and transcriptomics to reveal metabolic characteristics and key targets associated with cisplatin resistance in non-small cell lung cancer.

GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin

Cisplatin resistance in human cervical, ovarian and lung cancer cells

Effects of Cisplatin on Glucose - 6 - Phosphate Dehydrogenase Expression and Activity in HeLa Cells

PD‐0332991 Combined with Cisplatin Inhibits Nonsmall Cell Lung Cancer and Reversal of Cisplatin Resistance

Exogenous Glutathione Contributes to Cisplatin Resistance in Lung Cancer A549 Cells.

Polyphyllin II (PPII) Enhances the Sensitivity of Multidrug-resistant A549/DDP Cells to Cisplatin by Modulating Mitochondrial Energy Metabolism.

Synergistic Inhibitory Effect of Gliquidone Against Cisplatin‐Resistant Human Lung Adenocarcinoma

In Vitro and in Vivo Analysis of Metabolites Involved in the TCA Cycle and Glutamine Metabolism Associated with Cisplatin Resistance in Human Lung Cancer

Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells

Impaired Pentose Phosphate Pathway in the Development of 3D MCF-7 Cells Mediated Intracellular Redox Disturbance and Multi-Cellular Resistance Without Drug Induction